Kairos Pharma says Phase 1 ENV-105 plus Tagrisso trial shows no Grade 3+ toxicities in 13 patients
KAPA•Program target
The program targets acquired Tagrisso resistance in a market the company estimates at about USD 10 billion.
Dose-finding continues
The company said the clean early safety profile supports continued dose-finding toward a recommended Phase 2 dose.
Interim Phase 1 safety data
Kairos Pharma reported interim Phase 1 safety data for ENV-105 with AstraZeneca’s Tagrisso in EGFR-mutated advanced NSCLC.
No Grade 3 or higher toxicities tied to ENV-105 were seen in 13 treated patients.
